Skip to main content
SpringerLink
Log in

Pheochromocytoma and Paraganglioma

  • Chapter
  • First Online:
Secondary Hypertension

Part of the book series: Updates in Hypertension and Cardiovascular Protection ((UHCP))

  • 707 Accesses

Abstract

Catecholamine secreting tumors pheochromocytomas and paragangliomas (PPGLs) arise from the adrenal medulla and paravertebral ganglia of the sympathetic chain. Although PPGLs are rare, they may have severe and even fatal cardiovascular consequences. In patients with PPGLs, excessive release and high levels of circulating catecholamines are responsible for the classical symptoms of hyperadrenergic spells which among others include tachycardia, headache, and sweating and which may occur spontaneously or may be provoked by different physical or chemical triggers. When PPGLs are suspected, biochemical testing should precede imaging procedures and choosing the most appropriate laboratory test is crucial for reliable detection or exclusion of the tumor. Initial biochemical testing should include measurements of plasma free or urine fractionated metanephrines. After establishing a clear biochemical diagnosis, the next step is to localize the tumor. Computed tomography is recommended as the first-choice anatomical modality because of its excellent spatial resolution. Adequate preparation prior to surgical resection of the PPGLs is of relevance. Preoperative alpha-blockade has been advocated to lower blood pressure and minimize intra-operative hypertension. Beta-adrenoceptor blockade is indicated to control sinus tachycardia and other catecholamine-induced tachyarrhythmias, but only after several days of alpha-adrenoceptor blockade has been installed. After successful resection of PPGLs, patients should undergo long-term follow-up to detect recurrent tumors, new tumors, or metastatic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Darr R, Lenders JW, Hofbauer LC, Naumann B, Bornstein SR, Eisenhofer G. Pheochromocytoma—update on disease management. Ther Adv Endocrinol Metab. 2012;3:11–26.

    Article  Google Scholar 

  2. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:1915–42.

    Google Scholar 

  3. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366:665–75.

    Article  Google Scholar 

  4. Manger WM, Gifford RW Jr. Clinical and experimental pheochromocytoma. Cambridge, MA: Blackwell Science; 1996.

    Google Scholar 

  5. Neumann HPH, Young WF Jr, Eng C. Pheochromocytoma and paraganglioma. N Engl J Med. 2019;381:552–65.

    Article  CAS  Google Scholar 

  6. Prejbisz A, Lenders JW, Eisenhofer G, Januszewicz A. Cardiovascular manifestations of phaeochromocytoma. J Hypertens. 2011;29:2049–60.

    Article  CAS  Google Scholar 

  7. Pacak K, Keiser HR, Eisenhofer G. Pheochromocytoma. In: DeGroot LJ, Jameson JL, editors. Endocrinology. 5th ed. Philadelphia: Elsevier Saunders; 2006. p. 2501–34.

    Google Scholar 

  8. Pacak K, Wimalawansa SJ. Pheochromocytoma and paraganglioma. Endocr Pract. 2015;21:406–12.

    Article  Google Scholar 

  9. Prejbisz A, Lenders JW, Eisenhofer G, Januszewicz A. Mortality associated with phaeochromocytoma. Horm Metab Res. 2013;45:154–8.

    Article  CAS  Google Scholar 

  10. Berends AMA, Buitenwerf E, de Krijger RR, Veeger N, van der Horst-Schrivers ANA, Links TP, et al. Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: a nationwide study and systematic review. Eur J Intern Med. 2018;51:68–73.

    Google Scholar 

  11. Pamporaki C, Hamplova B, Peitzsch M, Prejbisz A, Beuschlein F, Timmers H, et al. Characteristics of pediatric vs adult pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2017;102:1122–32.

    Google Scholar 

  12. Soltani A, Pourian M, Davani BM. Does this patient have pheochromocytoma? A systematic review of clinical signs and symptoms. J Diabetes Metab Disord. 2015;15:6.

    Article  Google Scholar 

  13. Geroula A, Deutschbein T, Langton K, Masjkur JR, Pamporaki C, Peitzsch M, et al. Pheochromocytoma and paraganglioma: clinical feature based disease probability in relation to catecholamine biochemistry and reason for disease suspicion. Eur J Endocrinol. 2019;181:409–20.

    Google Scholar 

  14. Falhammar H, Kjellman M, Calissendorff J. Initial clinical presentation and spectrum of pheochromocytoma: a study of 94 cases from a single center. Endocr Connect. 2018;7:186–92.

    Article  CAS  Google Scholar 

  15. Gruber LM, Hartman RP, Thompson GB, McKenzie TJ, Lyden ML, Dy BM, et al. Pheochromocytoma characteristics and behavior differ depending on method of discovery. J Clin Endocrinol Metab. 2019;104:1386–93.

    Google Scholar 

  16. Agarwal V, Kant G, Hans N, Messerli FH. Takotsubo-like cardiomyopathy in pheochromocytoma. Int J Cardiol. 2011;153:241–8.

    PubMed  Google Scholar 

  17. Agrawal S, Shirani J, Garg L, Singh A, Longo S, Longo A, et al. Pheochromocytoma and stress cardiomyopathy: insight into pathogenesis. World J Cardiol. 2017;9:255–60.

    Google Scholar 

  18. Eisenhofer G, Rivers G, Rosas AL, Quezado Z, Manger WM, Pacak K. Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management. Drug Saf. 2007;30:1031–62.

    Article  CAS  Google Scholar 

  19. Langton K, Gruber M, Masjkur J, Steenblock C, Peitzsch M, Meinel J, et al. Hypertensive crisis in pregnancy due to a metamorphosing pheochromocytoma with postdelivery Cushing’s syndrome. Gynecol Endocrinol. 2018;34:20–4.

    Google Scholar 

  20. Lenders JW. Pheochromocytoma and pregnancy: a deceptive connection. Eur J Endocrinol. 2012;166:143–50.

    Article  CAS  Google Scholar 

  21. Lenders JWM, Langton K, Langenhuijsen JF, Eisenhofer G. Pheochromocytoma and pregnancy. Endocrinol Metab Clin N Am. 2019;48:605–17.

    Article  Google Scholar 

  22. Manger WM. The vagaries of pheochromocytomas. Am J Hypertens. 2005;18:1266–70.

    Article  Google Scholar 

  23. Eisenhofer G, Prejbisz A, Peitzsch M, Pamporaki C, Masjkur J, Rogowski-Lehmann N, et al. Biochemical diagnosis of chromaffin cell tumors in patients at high and low risk of disease: plasma versus urinary free or deconjugated o-methylated catecholamine metabolites. Clin Chem. 2018;64:1646–56.

    Google Scholar 

  24. Weismann D, Peitzsch M, Raida A, Prejbisz A, Gosk M, Riester A, et al. Measurements of plasma metanephrines by immunoassay vs liquid chromatography with tandem mass spectrometry for diagnosis of pheochromocytoma. Eur J Endocrinol. 2015;172:251–60.

    Google Scholar 

  25. Eisenhofer G, Lattke P, Herberg M, Siegert G, Qin N, Darr R, et al. Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromocytoma. Ann Clin Biochem. 2013;50:62–9.

    Google Scholar 

  26. Darr R, Pamporaki C, Peitzsch M, Miehle K, Prejbisz A, Peczkowska M, et al. Biochemical diagnosis of phaeochromocytoma using plasma-free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions. Clin Endocrinol. 2014;80:478–86.

    Google Scholar 

  27. Peitzsch M, Prejbisz A, Kroiss M, Beuschlein F, Arlt W, Januszewicz A, et al. Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatography-tandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma. Ann Clin Biochem. 2013;50:147–55.

    Google Scholar 

  28. Eisenhofer G, Lenders JW, Siegert G, Bornstein SR, Friberg P, Milosevic D, et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer. 2012;48:1739–49.

    Google Scholar 

  29. Eisenhofer G, Huynh TT, Pacak K, Brouwers FM, Walther MM, Linehan WM, et al. Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr Relat Cancer. 2004;11:897–911.

    Google Scholar 

  30. Canu L, Van Hemert JAW, Kerstens MN, Hartman RP, Khanna A, Kraljevic I, et al. Ct characteristics of pheochromocytoma: relevance for the evaluation of adrenal incidentaloma. J Clin Endocrinol Metab. 2019;104:312–8.

    Google Scholar 

  31. Sahdev A, Sohaib A, Monson JP, Grossman AB, Chew SL, Reznek RH. Ct and mr imaging of unusual locations of extra-adrenal paragangliomas (pheochromocytomas). Eur Radiol. 2005;15:85–92.

    Article  Google Scholar 

  32. Timmers HJ, Taieb D, Pacak K. Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma. Horm Metab Res. 2012;44:367–72.

    Article  CAS  Google Scholar 

  33. Rao D, van Berkel A, Piscaer I, Young WF, Gruber L, Deutschbein T, et al. Impact of 123 I-MIBG scintigraphy on clinical decision making in pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2019. publishe-ahead-of-print.

    Google Scholar 

  34. van Berkel A, Pacak K, Lenders JW. Should every patient diagnosed with a phaeochromocytoma have a (1)(2)(3) I-MIBG scintigraphy? Clin Endocrinol. 2014;81:329–33.

    Article  Google Scholar 

  35. Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015;35:500–16.

    Article  Google Scholar 

  36. Janssen I, Blanchet EM, Adams K, Chen CC, Millo C, Herscovitch P, et al. Superiority of [68Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma. Clin Cancer Res. 2015;21:3888–95.

    Google Scholar 

  37. Lepoutre-Lussey C, Caramella C, Bidault F, Deandreis D, Berdelou A, Al Ghuzlan A, et al. Screening in asymptomatic SDHx mutation carriers: added value of (1)(8)F-FDG PET/CT at initial diagnosis and 1-year follow-up. Eur J Nucl Med Mol Imaging. 2015;42:868–76.

    Google Scholar 

  38. Murai K, Hirota K, Niskikimi T, Kawarabayashi T, Yoshiyama M, Yasuda M, et al. Pheochromocytoma with electrocardiographic change mimicking angina pectoris, and cyclic change in direct arterial pressure—a case report. Angiology. 1991;42:157–61.

    Google Scholar 

  39. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;346:1459–66.

    Google Scholar 

  40. Neumann HP, Erlic Z, Boedeker CC, Rybicki LA, Robledo M, Hermsen M, et al. Clinical predictors for germline mutations in head and neck paraganglioma patients: Cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res. 2009;69:3650–6.

    Google Scholar 

  41. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, et al. Distinct clinical features of paraganglioma syndromes associated with sdhb and sdhd gene mutations. JAMA. 2004;292:943–51.

    Google Scholar 

  42. Favier J, Amar L, Gimenez-Roqueplo AP. Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol. 2015;11:101–11.

    Article  CAS  Google Scholar 

  43. Rogowski-Lehmann N, Geroula A, Prejbisz A, Timmers H, Megerle F, Robledo M, et al. Missed clinical clues in patients with pheochromocytoma/paraganglioma discovered by imaging. Endocr Connect. 2018;7:1168–77.

    Google Scholar 

  44. Eisenhofer G, Bornstein SR. Surgery: risks of hemodynamic instability in pheochromocytoma. Nat Rev Endocrinol. 2010;6:301–2.

    Article  Google Scholar 

  45. Malec K, Miskiewicz P, Witkowska A, Krajewska E, Toutounchi S, Galazka Z, et al. Comparison of phenoxybenzamine and doxazosin in perioperative management of patients with pheochromocytoma. Kardiol Pol. 2017;75:1192–8.

    Google Scholar 

  46. Mannelli M, Dralle H, Lenders JW. Perioperative management of pheochromocytoma/paraganglioma: is there a state of the art? Horm Metab Res. 2012;44:373–8.

    Article  CAS  Google Scholar 

  47. Plouin PF, Amar L, Dekkers OM, Fassnacht M, Gimenez-Roqueplo AP, Lenders JW, et al. European Society of Endocrinology clinical practice guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. 2016;174:G1–10.

    Google Scholar 

  48. Amar L, Fassnacht M, Gimenez-Roqueplo AP, Januszewicz A, Prejbisz A, Timmers H, et al. Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma. Horm Metab Res. 2012;44:385–9.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hypertension, National Institute of Cardiology, Warsaw, Poland

    Andrzej Januszewicz, Aleksander Prejbisz, Piotr Dobrowolski & Magdalena Januszewicz

Authors
  1. Andrzej Januszewicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aleksander Prejbisz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Piotr Dobrowolski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Magdalena Januszewicz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Piotr Dobrowolski .

Editor information

Editors and Affiliations

  1. Center of Clinical Physiology and Hypertension, Policlinic Hospital, University of Milan, Milan, Italy

    Alberto Morganti

  2. Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

    Enrico Agabiti Rosei

  3. Department of Medicine, Endocrine Unit, University of Padua, Padova, Italy

    Franco Mantero

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Januszewicz, A., Prejbisz, A., Dobrowolski, P., Januszewicz, M. (2020). Pheochromocytoma and Paraganglioma. In: Morganti, A., Agabiti Rosei, E., Mantero, F. (eds) Secondary Hypertension . Updates in Hypertension and Cardiovascular Protection. Springer, Cham. https://doi.org/10.1007/978-3-030-45562-0_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-45562-0_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-45561-3

  • Online ISBN: 978-3-030-45562-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation